Back to Browse Journals » Vascular Health and Risk Management » Volume 8

Ezetimibe therapy: mechanism of action and clinical update

Authors Phan BAP, Dayspring TD, Toth PP

Received 7 May 2012

Accepted for publication 23 May 2012

Published 3 July 2012 Volume 2012:8 Pages 415—427

DOI http://dx.doi.org/10.2147/VHRM.S33664

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Binh An P Phan,1 Thomas D Dayspring,2 Peter P Toth3

1Division of Cardiology, Loyola University Medical Center, Maywood, IL, USA; 2Foundation for Health Improvement and Technology, Wayne, NJ, USA; 3CGH Medical Center, Sterling, IL, USA

Abstract: The lowering of low-density lipoprotein cholesterol (LDL-C) is the primary target of therapy in the primary and secondary prevention of cardiovascular events. Although statin therapy is the mainstay for LDL-C lowering, a significant percentage of patients prescribed these agents either do not achieve targets with statin therapy alone or have partial or complete intolerance to them. For such patients, the use of adjuvant therapy capable of providing incremental LDL-C reduction is advised. One such agent is ezetimibe, a cholesterol absorption inhibitor that targets uptake at the jejunal enterocyte brush border. Its primary target of action is the cholesterol transport protein Nieman Pick C1 like 1 protein. Ezetimibe is an effective LDL-C lowering agent and is safe and well tolerated. In response to significant controversy surrounding the use and therapeutic effectiveness of this drug, we provide an update on the biochemical mechanism of action for ezetimibe, its safety and efficacy, as well as the results of recent randomized studies that support its use in a variety of clinical scenarios.

Keywords: bile, coronary artery disease, ezetimibe, low-density lipoprotein cholesterol, Nieman pick C1 like 1 protein, statin

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] View Full Text [HTML] 

 

Readers of this article also read:

Steroid for epidural injection in spinal stenosis: a systematic review and meta-analysis

Liu K, Liu PC, Liu R, Wu X, Cai M

Drug Design, Development and Therapy 2015, 9:707-716

Published Date: 30 January 2015

Biocomposite nanofibrous strategies for the controlled release of biomolecules for skin tissue regeneration

Gandhimathi C, Venugopal JR, Bhaarathy V, Ramakrishna S, Kumar SD

International Journal of Nanomedicine 2014, 9:4709-4722

Published Date: 8 October 2014

Serum lipid profile and correlates in newly presenting Nigerians with arterial hypertension

Adamu UG, Okuku GA, Oladele CO, Abdullahi A, Oduh JI, Fasae AJ

Vascular Health and Risk Management 2013, 9:763-768

Published Date: 3 December 2013

Adverse drug events associated with vitamin K antagonists: factors of therapeutic imbalance

El-Helou N, Al-Hajje A, Ajrouche R, Awada S, Rachidi S, Zein S, Salameh P

Vascular Health and Risk Management 2013, 9:81-88

Published Date: 1 March 2013

Comparative effect of clopidogrel plus aspirin and aspirin monotherapy on hematological parameters using propensity score matching

Hayasaka M, Takahashi Y, Nishida Y, Yoshida Y, Hidaka S, Asai S

Vascular Health and Risk Management 2013, 9:65-70

Published Date: 18 February 2013

Outcomes of patients treated with the everolimus-eluting stent versus the zotarolimus-eluting stent in a consecutive cohort of patients at a tertiary medical center

Shammas NW, Shammas GA , Nader E, Jerin M, Mrad L, Marogil P, Henn C, Dvorak A, Chintalapani A, Meriner S

Vascular Health and Risk Management 2012, 8:205-211

Published Date: 11 April 2012

Real-world effectiveness of valsartan on hypertension and total cardiovascular risk: review and implications of a translational research program

Abraham I, MacDonald K, Hermans C, Aerts A, Lee C, Brié H, Vancayzeele S

Vascular Health and Risk Management 2011, 7:209-235

Published Date: 31 March 2011

The western diet and lifestyle and diseases of civilization

Pedro Carrera-Bastos, Maelan Fontes-Villalba, James H O’Keefe, et al

Research Reports in Clinical Cardiology 2011, 2:15-35

Published Date: 9 March 2011